Identification of anti‐inflammatory drugs according to their capacity to suppress type‐1 and type‐2 T cell profiles

Abstract

Using a contact allergy model, we have demonstrated that various AIDs show distinct pharmacological profiles in that either type-1 or type-2 or both T cell responses are suppressed. These results should contribute to a more rational selection of AID in treating inflammatory skin diseases mediated by either or both of these T cell subsets.